Tarsus Pharmaceuticals, Inc. TARS Debt Issuance Costs, Line of Credit Arrangements, Net
Other financials
Where this comes from
Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:DebtIssuanceCostsLineOfCreditArrangementsNet.
The official record: Tarsus Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Tarsus Pharmaceuticals, Inc.'s debt issuance costs, line of credit arrangements, net.
Connect your AI assistant and see it in context, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Tarsus Pharmaceuticals, Inc.'s debt issuance costs, line of credit arrangements, net?
- Tarsus Pharmaceuticals, Inc. (TARS) reported debt issuance costs, line of credit arrangements, net of $3.52M in Q1 2026.
- How has Tarsus Pharmaceuticals, Inc.'s debt issuance costs, line of credit arrangements, net changed year-over-year?
- Tarsus Pharmaceuticals, Inc.'s debt issuance costs, line of credit arrangements, net decreased by 0.0% year-over-year, from $3.52M to $3.52M.
- What is the long-term trend for Tarsus Pharmaceuticals, Inc.'s debt issuance costs, line of credit arrangements, net?
- Over 3 years (2022 to 2025), Tarsus Pharmaceuticals, Inc.'s debt issuance costs, line of credit arrangements, net has grown at a 59.1% compound annual growth rate (CAGR), from $875K to $3.52M.